Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Xevudy Delivery for 80,000 People Begins Ahead of Schedule: Health Minister
February 24, 2022
- No Reasonable Link between COVID-19 Vaccinations and Excess Deaths: MHLW Panels
February 22, 2022
- PMDA Reviewing New Safety Risks for Brilinta, Stocrin, Ofev
February 21, 2022
- All Company-Led Post-Marketing Studies Should Be Regulated by PMD Law upon Clinical Research Law Amendment: Panel
February 21, 2022
- Japan Weighs Pre-Approval Purchase of Shionogi’s COVID-19 Pill
February 21, 2022
- AZ’s Asthma Drug, Takeda HAE Med, Novartis CML Therapy and More Up for PAFSC Review on March 3
February 18, 2022
- Komeito Hears Update on Mitsubishi Tanabe’s COVID-19 Vaccine
February 18, 2022
- LDP Health Committee OKs Bill to Amend PMD Law
February 18, 2022
- Key Resource Suppliers to Be Fined for False Reporting: Draft Economic Security Bill
February 17, 2022
- MHLW Flags Xevudy Supply Disruption, Calls for Use of Other COVID-19 Drugs
February 17, 2022
- MHLW Calls for Considering Veklury Use as Tight Supply Expected for Xevudy
February 16, 2022
- Lawmakers Mixed on Use of Conditional Approval for Shionogi’s COVID-19 Pill
February 16, 2022
- Japan Approves Slew of Generics towards June Listing; Samsca, Xarelto AGs Too
February 16, 2022
- Japan Snags 10 Million Extra Doses of Pfizer Vaccine
February 15, 2022
- Japan Panel OKs Free COVID-19 Vaccination for Ages 5-11, but No “Effort” Obligation Applied
February 14, 2022
- MHLW Panel to Review Bayer’s CKD Drug Finerenone Again on Feb. 25
February 14, 2022
- Pfizer’s Paxlovid Contraindicated with Many Medicines, Requires Careful Use
February 14, 2022
- Japan Approves Pfizer’s Paxlovid, Second Oral COVID-19 Pill
February 10, 2022
- LDP Health Committee to Review PMD Law Amendment Bill Mid-February
February 10, 2022
- Chuikyo Issues 2022 Reform Recommendation; Patch Prescription Limit Lowered to 63 Sheets
February 10, 2022
ページ
Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…